Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 3

Interventions

Mitomycin 12Gemcitabine 9BCG Vaccine 4apaziquone 3Epirubicin 3erdafitinib 2durvalumab 2dodecyl maltoside 2VB4-845 2Docetaxel 2viscum album peptide 1valrubicin 1pirarubicin 1hydroxycamptothecinum 1Transurethral Resection of Bladder 1Therapeutic Uses 1Standard of Care 1Saline Solution 1Radiotherapy 1Polysorbates 1Maintenance 1Magnetic Resonance Spectroscopy 1Injections 1Cystoscopy 15-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Non-Muscle Invasive Bladder Neoplasms × apaziquone × Clear all
NCT02563561 2021-10-27

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
62 enrolled 10 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01469221 2017-12-15

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
47 enrolled 11 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01410565 2016-12-13

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
66 enrolled 12 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡